HTEC to Support Digital Telco Enabler Telness Tech in Platform Software Development
17.9.2024 18:31:00 CEST | Business Wire | Press release
Telness Tech, a fast-growing international software company founded in Sweden, and HTEC, a global end-to-end digital product development and engineering services company, are pleased to announce their work on Telness Tech’s innovative platform, which will support the company’s ongoing expansion into new markets, like the US.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240917678716/en/
In this partnership, HTEC will support Telness Tech by providing additional engineering expertise for the new platform’s deployment, customization, and user migration from legacy platforms. HTEC will also assist in the development of business-to-consumer (B2C) applications and various network integrations, including building an abstraction layer for easier integrations. (Graphic: Business Wire)
The platform’s proprietary software is a cloud-based, end-to-end solution for mobile virtual network operators (MVNOs) that offers comprehensive operations and business support system (OSS/BSS) capabilities. It streamlines and automates the customer journey, deploying quickly and remotely without the need for traditional telco infrastructure or legacy IT systems. The platform has already helped Telness Tech clients boost customer ratings in Europe.
In the partnership, HTEC will support Telness Tech by providing additional engineering expertise for the new platform’s deployment, customization, and user migration from legacy platforms. HTEC will also assist in the development of business-to-consumer (B2C) applications and various network integrations, including building an abstraction layer for easier integrations.
Commenting on the collaboration, HTEC’s Director of Engineering & Delivery Bojan Šukalo said:
“Recent tech innovations have transformed how we communicate, but many in the telco industry still use traditional infrastructure. With HTEC’s technical expertise and engineering capacity, we’re perfectly positioned to support the industry’s digital transformation and aligned with Telness Tech to steer the industry forward.”
Founder and COO of Telness Tech, Jonas Cedenwing, highlighted the value of HTEC’s support in this expansion:
“With high demand for our software across the globe, partnering with HTEC ensures that our clients’ platform demands and transitions remain smooth and streamlined, enabling us to continue our high expansion rate without compromising quality.”
About Telness Tech
Founded in Sweden with offices in the US, Telness Tech provides everything needed to launch or run a fully automated mobile operator. The company’s end-to-end BSS/OSS solutions streamline customer journeys, provisioning, and porting — necessary functions to run a digital mobile operator. As a result, satisfied clients drastically reduce operational costs.
About HTEC
HTEC Group Inc. is a global premium technology services firm powering the technological evolution of the world’s most impactful organizations—from disruptive startups to the Fortune 500. HTEC combines deep engineering expertise with remarkable creativity, enabling its customers to innovate, design, and develop disruptive technologies and new digital solutions across different industries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917678716/en/
Contacts
HTEC Media Relations: media@htecgroup.com
HTEC Media Relations: media@htecgroup.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom